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Molecular genetic diagnostic strategies of cystic ﬁbrosis (CF) are dependent of the
mutation distribution of the analyzed population. The goal of our study was to
establish the mutational spectrum of 39 clinically diagnosed severe CF patients in
Eastern Hungary.
For the mutation testing, multiplex commercially available diagnostic assays were
used and in patients having mutation not included in the panel, the entire coding
region of the CFTR gene was sequenced.
Using the mutation detection kits only, the detection rate was 81%. When DNA
sequencing was used, disease-causing mutations could be detected in 77 out of
the 78 CFTR alleles (99% diagnostic sensitivity). Presence of six mutations (delta
F508, CFTRdele2,3(21kb), 2184insA, N1303K, G542X and L101X) was shown in
91% of CF chromosomes.
Our results suggest that in Eastern Hungary the majority of CF-causing mutations
are small-scale. Two mutations (CFTRdele2,3(21kb), 2184insA) were found in
surprisingly high frequency.
Based on our data, the Eastern Hungarian CF mutation testing panel can be
established.
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At present time, CFTR mRNA analysis represents more a research tool for the
identiﬁcation of unknown molecular defects of the CFTR gene in speciﬁc rare
cases than a routine approach to complete a diagnostic procedure. In particular
mRNA analysis may allow researchers to ﬁnd sequence variations not yet deﬁned
like speciﬁc splicing defects. Molecular analysis of CFTR performed at DNA level
on 800 patients was not able to identify the defect in 101 (6%) CF alleles. In
order to characterize these unidentiﬁed alleles, 36 cases out of 50 patients were
re-contacted and a nasal epithelium sample was collected to analyze the mRNA.
The RNA defects were characterized in about the 30.5 % of analyzed patients. The
cDNA analysis showed that 8 patients had a novel transcription product: 4 patients
carry an insertion of intron sequence of about 100bp near exon 6b, 2 patients carry
a 104 bp insertion located between exons 10 and 11; 2 patients presented at DNA
level a nucleotide variation described as polymorphism, which instead determines
an aberrant splicing at RNA level.
In addition in 2 patients we observed a low level of mRNA product that will be
analyzed by quantitative technique. The remaining patients are still under evaluation.
Our results conﬁrm the efﬁcacy of the CFTR analysis at mRNA level as a diagnostic
method in characterizing mutations and in checking their effect on normal splicing
processes and transcription rates.
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The Czech Republic is ethnically relatively homogenous country with incidence
1:2700–1:4023 (from newborn screening data). The molecular-genetic diagnostics
of CF is complicated as more than 1600 variations have been described to date.
Here we present comprehensive study on the distribution of CF-causing mutations
in representative cohort of 560 Czech CF patients collected in the “main reference”
CFC in Prague during years 1990–2009. CFTR mutation analysis is provided
by “cascade” strategy. Initially we test the most common mutations (p.F508del,
c.CFTRdele2.3/21kb/, p.G551D, p.G542X, p.R553X, p.N1303K and c.2143delT) by
RFLP in combination with PCR with ﬂuorescent labelled primers and duplex PCR.
In next step we use commercial available kits. These routine methods are followed
by MLPA, HRM and sequencing, which allow reliable detection of rare and un-
known mutations. Totally we identiﬁed 1113/1120 CF alleles (99.38%), from that 17
cases were detected by newborn screening. We detected 83 different mutations, only
eight of these (p.F508del − 67.2%, c.CFTRdele2.3/21kb/ − 5.9%, p.G551D − 3%,
p.N1303K − 2.6%, p.G542X − 2%, c.3849+10kbC>T − 1.8%, c.1898A+1G>A −
1.3%, c.2143delT − 1.1%) were more common with frequency >1%. More than
half of all mutations is private. Totally we revealed 13 new mutations which haven’t
been described in CFMDB yet. A high heterogeneity of mutations was found in
the Czech Republic. Our approach with using extended analysis (MLPA, HRM and
sequencing) brought in signiﬁcant improvement in detection rate about 6.9% and
helped to conﬁrmed CF diagnosis at 77 CF patients (13.7% of all patients).
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Using highly parallel pyrosequencing, we have developed two CFTR genetic test
formats.
In a ﬁrst format, the complete coding region and exon/intron junctions of the CFTR
gene are sequenced in an amplicon sequencing approach. Since that pyrosequencing
may not correctly call homo-polymeric nucleotide stretches, we included tagged
ARMS primers at such positions, so that the number of nucleotides can also
be called through their tag, besides counting the number of nucleotides that are
obtained in homo-polymeric nucleotide stretches in reads. The different amplicons
for different patient samples are ampliﬁed in parallel on a microﬂuidic chip. To
increase robustness, 2 amplicons are generated for each region, in which one test
result can be used for quality-assurance of the other test result.
In a second format, the complete 180kb CFTR gene is sequenced by long range
PCR and a subsequent shotgun approach.
Quality-assurance of the complete genetic test process and automatic processing
was realized by spiking samples with DNA molecules. These molecular bar codes
can be processed simultaneously with the DNA fragments under investigation. The
test will be quality-assured from the moment that the sample is spiked. The test will
be only valid when the correct spiked sample tag is associated with the molecular
bar code at the end of process. Not only can sequencing reveal a mutation, it will
also identify the sample carrying the mutation. This allows automatic generation
of a report, thereby excluding potential errors compared to reports generated by
human intervention when test result and patient information are brought together
in a genetic report.
